Barclays upgraded Thermo Fisher (TMO) to Overweight from Equal Weight with a price target of $550, up from $490. The company’s valuation, both on an absolute and relative basis, is now now at attractive levels, the analyst tells investors in a research note. The firm believes Thermo’s end market demand is stable and should improve modestly over the next few years. Meanwhile, management’s mid-term guidance reset “sets a floor” with little additional downside risk to numbers, contends Barclays.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Lemonade, Western Digital, CoreWeave, Autodesk, and Thermo Fisher: Insider Sales Shake the Market!
- Thermo Fisher price target lowered to $561 from $572 at RBC Capital
- Thermo Fisher Completes $4 Billion Solventum Acquisition
- CSX, CVS, Lowe’s, Target, Thermo Fisher: Trending by Analysts
- Palo Alto upgraded, Li Auto downgraded: Wall Street’s top analyst calls